NASH? LOL! Chenodiol is generic, plus look at the safety profile on the label.
Although I've spent less than 30 minutes researching (so far) I'd still give it a 30-40% chance that he/they find a way to sell it for NASH to a substantial fraction of the NASH population before ICPT's drug finishes its ph 3 and is approved for NASH.
E.g. the label itself notes that the liver tox may be limited to a specific genetic population. That said, not sure how they would overcome the "generic" issue. But at this point I am willing to give Shkrelli at least a little benefit of the doubt. FWIW.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.